KLK3 and prostate carcinoma: If prospective trials do in fact demonstrate that measurable growth rates are altered by immune therapies, it may be possible to use disease-specific parameters such as PSA in prostate cancer, M-spike in multiple myeloma, and tumor size in renal cell cancer as surrogates for response to treatment [81].